BioStock: Annexin summarizes Q1: promising study data and fully subscribed issue
Annexin Pharmaceuticals has entered 2025 with clear progress on two fronts – clinical development and financing. The final analysis from the Phase IIa study in retinal vein occlusion confirms the potential of the drug candidate, with positive efficacy signals and a favorable safety profile, while a recently completed rights issue provides resources to accelerate development.
Read more at biostock.se